Quick Answer
Saffron Appetite Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: However, due to some potentially significant adverse events associated with its medicinal use at higher doses or prolonged administration, clinical monitoring should be considered.
Key Takeaways
- 01However, due to some potentially significant adverse events associated with its medicinal use at higher doses or prolonged administration, clinical monitoring should be considered. [Hasheminasab FS (2026)]
- 02Background Crocus sativus L., commonly known as saffron, is a widely used spice with a rich history of culinary and medicinal applications. [Hasheminasab FS (2026)]
- 03This systematic review aims to compile human data from studies on monopreparations of C. [Hasheminasab FS (2026)]
- 04Dysregulated adipogenesis in obesity involves excessive preadipocyte recruitment and differentiation, leading to increased adipocyte number (hyperplasia) and hypertrophy. [Marie Ohoud M. (2026)]
The current Migaku evidence database contains 2 reusable source documents for Saffron Appetite Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- However, due to some potentially significant adverse events associated with its medicinal use at higher doses or prolonged administration, clinical monitoring should be considered. [Hasheminasab FS (2026); evidence level 1]
- Background Crocus sativus L., commonly known as saffron, is a widely used spice with a rich history of culinary and medicinal applications. [Hasheminasab FS (2026); evidence level 1]
- This systematic review aims to compile human data from studies on monopreparations of C. [Hasheminasab FS (2026); evidence level 1]
- Dysregulated adipogenesis in obesity involves excessive preadipocyte recruitment and differentiation, leading to increased adipocyte number (hyperplasia) and hypertrophy. [Marie Ohoud M. (2026); evidence level 3]
- In obesity, lipolytic capacity is suppressed through multiple mechanisms including impaired sympathetic nervous system signaling and reduced expression of lipolytic enzymes (Thorp and Schlaich ). [Marie Ohoud M. (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources